Tonix Pharmaceuticals Presents Real-World Data Highlighting High Burden of Fibromyalgia at ISPOR 2026
May 26th, 2026 1:58 PM
By: Newsworthy Staff
Tonix Pharmaceuticals presented data at ISPOR 2026 showing that over 93% of fibromyalgia patients have comorbidities and incur substantial healthcare costs, underscoring the need for more effective treatments like its newly approved TONMYA.
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) presented real-world claims analysis data at the ISPOR 2026 conference, highlighting the significant clinical and economic burden of fibromyalgia in U.S. adults. The findings, based on a retrospective analysis of more than 261,000 adult fibromyalgia patients, revealed that over 93% had at least one fibromyalgia-related comorbidity, and insured patients faced substantial annual healthcare costs driven primarily by inpatient services. This underscores the unmet need for more effective long-term treatment options as Tonix advances its planned commercial launch of TONMYA (cyclobenzaprine HCl sublingual tablets 2.8 mg), the first new treatment for fibromyalgia in more than 15 years.
The analysis demonstrated extensive healthcare resource utilization and widespread reliance on multimodal treatment approaches among fibromyalgia patients. The high comorbidity rates and costs highlight the burden of this condition, which affects millions of Americans. Tonix's presentation at ISPOR 2026 provides critical real-world evidence to support the potential value of TONMYA in addressing this unmet medical need.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. In addition to TONMYA, Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products Zembrace SymTouch and Tosymra. The company is also maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder.
Further, Tonix's CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. The company is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. For the latest news and updates relating to TNXP, visit the company's newsroom at https://ibn.fm/TNXP.
The full press release is available at https://ibn.fm/yMppz.
Source Statement
This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,
